empty

Novel HIV drug introduced

HIV still infects thousands of people across the UK. Government statistics suggest that 4,139 people were diagnosed with HIV during 2019 and that, overall, 98,552 people received care for HIV in the UK during the year.

With antiviral resistance remaining an issue, ViiV Healthcare recently launched fostemsavir (Rukobia), which, in combination with other antiretrovirals, treats adults with multidrug resistant HIV-1 infection “for whom it is otherwise not possible to construct a suppressive antiviral regimen”.

Fostemsavir is a prodrug. The active metabolite (temsavir) inhibits the interaction between HIV and CD4 receptors, which prevents HIV from entering and infecting cells.

Patients take 600mg fostemsavir twice daily. Sixty 600mg prolonged-release tablets cost £2,900.



This website is for healthcare professionals, people who work in pharmacy and pharmacy students. By clicking into any content, you confirm this describes you and that you agree to Pharmacy Network News's Terms of Use and Privacy Policy.

We use essential, performance, functional and advertising cookies to give you a better web experience. Find out how to manage these cookies here. We also use Interest Based Advertising Cookies to display relevant advertisements on this and other websites based on your viewing behaviour. By clicking "Accept" you agree to the use of these Cookies and our Cookie Policy.